Open an account

Matinas BioPharma Holdings

MTNB · NYSE American

$1.70+$0.2288 (+15.55%)TodayMarket closed ·
Prev close $1.47

About MTNB

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 2 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Employees
2
Headquarters
Bedminster, New Jersey
Listed
Jun 3, 2014
Sector
Health Care
Industry
Biotechnology
Website
matinasbiopharma.com

MTNB key statistics

Market cap
1.67M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
754.83K
Volume
1
Open price
$1.66
High today
$1.72
Low today
$1.51
52 Week high
$1.99
52 Week low
$0.1505

Matinas BioPharma Holdings (MTNB) at a glance

Matinas BioPharma Holdings (MTNB) last traded at $1.70, with a market cap of 1.67M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.51 and $1.72. The current price is 12.6% above the day's low and 1.2% below its high.

Volume so far is 1 shares, below the average of 754.83K shares a day.

Over the past year Matinas BioPharma Holdings has ranged from $0.1505 to $1.99, and now sits 84% of the way up that range.

Matinas BioPharma Holdings met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q4 FY24 it reported -$0.82 per share against an estimate of -$0.9078.

MTNB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 11.8% on average.

  1. Q1 FY23: reported -$1.50 per share against an estimate of -$1.53
  2. Q2 FY23: reported -$1.50 per share against an estimate of -$1.53
  3. Q3 FY23: reported -$1.50 per share against an estimate of -$1.53
  4. Q4 FY23: reported -$1.00 per share against an estimate of -$1.53
  5. Q1 FY24: reported -$1.50 per share against an estimate of -$1.53
  6. Q2 FY24: reported -$1.00 per share against an estimate of -$1.27
  7. Q3 FY24: reported -$0.85 per share against an estimate of -$1.08
  8. Q4 FY24: reported -$0.82 per share against an estimate of -$0.9078

MTNB news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseBusiness Wire

    GH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine Project

  • Avi Kapoor

    Nasdaq Surges Over 100 Points; Bank of America Earnings Top Views

  • Press releaseBusiness Wire

    GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma

Similar companies

Companies in the same industry as Matinas BioPharma Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.